These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 334212)

  • 1. Metabolic effects of fenfluramine in obese diabetics.
    Larsen S; Vejtorp L; Hornnes P; Bechgaard H; Sestoft L; Lyngsoe J
    Br J Clin Pharmacol; 1977 Oct; 4(5):529-33. PubMed ID: 334212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between metabolic responses to fasting in obese diabetic and obese nondiabetic subjects.
    Jackson RA; Moloney M; Lowy C; Wright AD; Hartog M; Pilkington TR; Fraser TR
    Diabetes; 1971 Apr; 20(4):214-27. PubMed ID: 4927927
    [No Abstract]   [Full Text] [Related]  

  • 3. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo.
    Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of obesity with fenfluramine.
    Persson I; Andersen U; Deckert T
    Eur J Clin Pharmacol; 1973 Aug; 6(2):93-7. PubMed ID: 4588854
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenfluramine therapy in non-insulin-dependent diabetic patients: effects on body weight, glucose homeostasis, serum lipoproteins, and antipyrine metabolism.
    Salmela PI; Sotaniemi EA; Viikari J; Solakivi-Jaakkola T; Järvensivu P
    Diabetes Care; 1981; 4(5):535-40. PubMed ID: 6751729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of fenfluramine on obese, maturity-onset diabetic patients.
    Wales JK
    Acta Endocrinol (Copenh); 1979 Apr; 90(4):616-23. PubMed ID: 373358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained decreases in weight and serum insulin, glucose, triacylglycerol and cholesterol in JCR:LA-corpulent rats treated with D-fenfluramine.
    Brindley DN; Hales P; al-Sieni AI; Russell JC
    Br J Pharmacol; 1992 Mar; 105(3):679-85. PubMed ID: 1628154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of fenfluramine on glucose uptake in vitro and in vivo.
    Jorgensen KD
    Acta Pharmacol Toxicol (Copenh); 1977 Mar; 40(3):401-17. PubMed ID: 139077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glucose tolerance, insulin and lipids after one week's administration of fenfluramine to overweight patients (author's transl)].
    Weisweiler P; Schwandt P
    MMW Munch Med Wochenschr; 1975 Nov; 117(48):1925-8. PubMed ID: 813120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of obesity with fenfluramine (Ponderal)].
    Persson I; Andersen UD; Deckert T
    Ugeskr Laeger; 1973 Sep; 135(36):1932-7. PubMed ID: 4590075
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity-onset diabetics.
    Dykes JR
    Postgrad Med J; 1973 May; 49(571):318-24. PubMed ID: 4804456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal normoglycemia attained with chlorpropamide in mild diabetes.
    Holman RR; Turner RC
    Metabolism; 1978 May; 27(5):539-47. PubMed ID: 565457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fenfluramine on human growth hormone release.
    Sulaiman WR; Johnson RH
    Br Med J; 1973 May; 2(5862):329-32. PubMed ID: 4704518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fenfluramine on insulin/growth hormone ratio in obese subjects.
    Altomonte L; Zoli A; Ghirlanda G; Manna R; Greco AV
    Pharmacology; 1988; 36(2):106-11. PubMed ID: 3281173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine.
    Russell JC; Dolphin PJ; Graham SE; Amy RM; Brindley DN
    Diabetologia; 1998 Apr; 41(4):380-9. PubMed ID: 9562341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexfenfluramine in type II diabetes: effect on weight and diabetes control.
    Stewart GO; Stein GR; Davis TM; Findlater P
    Med J Aust; 1993 Feb; 158(3):167-9. PubMed ID: 8450782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects.
    Glaser B; Raveh Y; Norynberg C; Berry E; Lavielle R; Nathan C; Cerasi E
    Diabetes Res; 1992; 19(4):165-76. PubMed ID: 1343113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal and metabolic studies of the action of fenfluramine in normal man, obesity, acromegaly and diabetes mellitus.
    Sulaiman WR; Johnson RH; Rennie MJ
    Postgrad Med J; 1975; 51 Suppl 1():125-31. PubMed ID: 1219669
    [No Abstract]   [Full Text] [Related]  

  • 19. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
    Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added benfluorex in obese insulin-requiring type 2 diabetes.
    Leutenegger M; Bauduceau B; Brun JM; Guillon-Metz F; Martin C; Nicolino-Peltier C; Richard JL; Vannereau D
    Diabetes Metab; 1998 Feb; 24(1):55-61. PubMed ID: 9534010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.